Table 1.

Summary of case reports documenting development of acute pulmonary tuberculosis in cancer patients treated with PD-1 inhibitors.

Patient(s)		Country of origin of report	Type of malignancy	PD-1 inhibitor	Outcome	References
Age	Gender
87	M	Singapore	Hodgkin's lymphoma	Pembrolizumab	Survived	(7)
72	M	Japan	NSCLC*	Nivolumab	Not reported	(8)
59	M	China	Stage 4 pulmonary adenocarcinoma	Nivolumab	Survived	(10)+
50	M	France	Metastatic melanoma	Pembrolizumab	Survived	(9)
64	M	France	NSCLC	Nivolumab	Died	(9)
65	F	China	Advanced melanoma	Pembrolizumab	Survived	(11)
56	M	Denmark	NSCLC	Nivolumab	Not reported	(12)
49	M	Taiwan	Stage 4 squamous cell carcinoma of hard palate	Nivolumab	Died	(13)
59	M	USA	Nasopharyngeal carcinoma	Nivolumab	Died	(14)
83	M	USA	Merkel cell carcinoma	Pembrolizumab	Survived	(14)
75	M	Japan	Lung adenocarcinoma	Nivolumab	Sruvived	(15)

^*Non-small cell lung carcinoma;

⁺patient with pericardial tamponade.